TNFRSF17 and plasma cell myeloma: Since 2017, several drugs have been developed for the therapy of hematologic diseases, such as B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma (CD19-directed: Kymriah (7), Yescarta (8), Tecartus (9), Breyanzi (10), Carteyva (11), ARI-0001 (12), NexCAR19 (13), Obe-Cel (14)), and multiple myeloma (BCMA-directed: Abecma (15), Carvykti (16), Fucaso (17)).